Articles tagged with Antibody Therapy
Researchers at Berkeley Lab have made significant breakthroughs in developing a highly effective COVID-19 antibody therapy and an efficient thermoelectric system that can convert waste heat to electricity. The new antibody, S309, has been shown to neutralize all known SARS-CoV-2 strains and may be more difficult for new mutants to escape.
Researchers analyzed patient specimens and clinical trial data from thousands of patients to assess the importance of immune cell molecules called Fc gamma receptors (FCGRs) in the therapeutic efficacy of two antibody drugs. High levels of FCGR2B on tumor cells were found to prevent rituximab efficacy, while obinutuzumab was not impact...
Researchers at NYU Langone Health have developed an antibody therapy that rescues mice from a lethal muscle-weakening disease by targeting another protein in the same signaling pathway. The treatment reverses disease relapse in adult mice, offering new hope for humans with congenital myasthenia.
Research suggests that combination therapies made from two antibodies retain potency against a wide range of COVID-19 variants, preventing emergence of drug resistance. The findings support the use of combination therapy for treating infections with this virus as more variants emerge.
A recent study published in Open Forum Infectious Diseases found that monoclonal antibody therapy is safe and effective in treating mild to moderate cases of COVID-19 in transplant patients. The study showed that these patients had a lower risk of severe illness and death compared to those who did not receive the treatment.
A new engineered IgM antibody therapy has been found to be significantly more potent than standard IgG antibodies at neutralizing the COVID-19 virus in animal models. The therapy, IGM-6268, demonstrated increased potency against emerging variants of concern and variants of interest.
Centivax has entered into a strategic partnership with the US Naval Medical Research Center to develop Centi-B9, a broad-spectrum injectable antibody therapeutic and prophylactic for COVID-19. The Phase I trial aims to demonstrate safety and pharmacokinetics of Centi-B9 in healthy volunteers.
Researchers have developed an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus, a highly lethal tick-borne disease. The therapy, called DVD-121-801, overcomes infection in mice with just one dose administered after virus exposure.
Researchers at the University of Zurich have developed a new technology called SHREAD that enables cancer tumors to produce therapeutic agents on demand, reducing side effects and improving delivery of Covid-related therapies.
The ACTIV-2 trial is testing SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19. The trial will enroll participants with mild or moderate cases of the disease and evaluate its safety and efficacy.
A CHOP-led research study found that B cell activating factor (BAFF) levels are elevated in patients resistant to coagulation protein therapy, suggesting a potential target for new treatments. Anti-BAFF therapies combined with immune tolerance therapies may tame the immune response in some patients with severe hemophilia A.
Researchers at Duke University developed self-assembling nanofibers that activate key cells in the immune system to limit damaging inflammation. The nanofibers, which include a protein called C3dg, were shown to be effective in treating psoriasis and other inflammatory diseases.
A new research study analyzed COVID-19 antibodies in asymptomatic patients and found that only 6 individuals produced sufficient neutralizing antibodies, while others developed high antibody levels with poor neutralization capabilities.
Scientists visualized anti-CD20 antibody effects in tumors using innovative imaging, finding macrophages play a crucial role in therapy efficacy. The study suggests increasing macrophage presence could boost therapeutic antibody effectiveness.
A new study published in the Journal of Nuclear Medicine found that combining radionuclide therapy with immunotherapy can slow prostate cancer progression and increase survival time. The treatment promotes prostate cancer immunogenicity, making tumors more receptive to immunotherapy.
Researchers found that combining unmodified anti-tumor antibodies with MEKi and immune checkpoint blockade generated a robust adaptive anti-tumor response, sustained by immune checkpoint inhibition. This combination therapy showed improved therapeutic efficacy in mouse models of melanoma.
Scientists from the University of Rome Tor Vergata created a method to use antibodies to control chemical reactions forming therapeutic agents and imaging molecules. The approach involves modifying synthetic DNA oligonucleotides with recognition elements targeting specific antibodies.
Researchers have developed a new type of precise therapeutic vaccine against leukemia utilizing self-healing polylactic acid microcapsules. The vaccine co-encapsulates a new epitope peptide and PD-1 antibody, demonstrating superior performance over commercialized adjuvants in various models.
Researchers at Pohang University of Science & Technology developed a novel immunotherapy platform called imuGlue, which connects mussel adhesive proteins to antibodies used in immune checkpoint inhibitors.
Researchers develop a combination therapy using near-infrared light-induced heat and anti-CD47 antibody to enhance cancer treatment. The treatment promotes local and systemic anticancer immune responses, showing great potential for solid tumors.
Researchers at University of Pittsburgh isolated the smallest biological molecule to date that neutralizes SARS-CoV-2. The tiny antibody component, known as Ab8, is 10 times smaller than a full-sized antibody and has been shown to be highly effective in preventing and treating SARS-COV-2 infection in mice and hamsters.
Researchers at the University of Texas at Austin have developed an antibody test for COVID-19 that is highly accurate and can handle a large number of donor samples. The test measures antibodies against specific proteins on the virus's spike protein and has been shown to be comparable to the gold standard of antibody testing.
Scientists have observed interaction between therapeutic antibodies and target protein for first time, describing molecular mechanisms. This discovery opens way to development of new synthetic antibodies controlling patient's immune response.
Researchers have discovered that a single molecular descriptor can predict the solution behavior of therapeutic antibodies with greater than 90% accuracy. This finding could enable faster and more efficient drug development for monoclonal antibody-based therapies.
Researchers at Mayo Clinic have found that investigational convalescent plasma is safe to use in a diverse group of 20,000 patients, with a significant decline in seven-day mortality rates compared to previous studies. The study also found lower serious adverse events and a more rapid availability of plasma for treatment.
A team of researchers at the University of Maryland School of Medicine has developed a potent antibody cocktail that can treat COVID-19 by targeting the virus's spike protein. The cocktail will be tested in a clinical trial to evaluate its effectiveness in improving patient outcomes.
Researchers have identified pairs of highly potent individual antibodies that can simultaneously bind SARS-CoV-2's spike protein, increasing chances against 'virus escape mutants'. The double-antibody approach aims to minimize odds of virus escape and deliver optimal antiviral potency.
A randomized trial found that rituximab reduces the risk of relapse by 64% compared to azathioprine, with fewer severe adverse events. The study suggests that rituximab may be a superior treatment option for patients with ANCA-associated vasculitis, particularly those with history of relapses.
A monoclonal antibody targeting mutant huntingtin protein effectively binds and depletes the protein from cell culture supernatants, blocking its secretion and uptake. This suggests that mAB C6-17 could interfere with pathological processes of mutant huntingtin spreading in vivo.
Two neutralizing antibodies, B38 and H4, have been identified against SARS-CoV-2. Preliminary tests in a mouse model show reduced virus titers, suggesting therapeutic benefits and potential for vaccine development.
A new approach using harmless viruses to deliver antibody genes has led to sustained production of HIV antibodies for over a year in a NIH clinical trial. The technology shows promise for preventing and treating various infectious diseases with further development.
Researchers have found that combining two anti-HIV antibodies with ART can suppress the virus and boost T cell responses, offering new hope for HIV treatment. The study suggests a potential interaction between humoral immunity and cell-mediated immunity, which could lead to improved control of the virus.
A new non-invasive imaging technique using 89Zr-immuno-PET can measure target engagement of therapeutic antibodies in tumors, enabling personalized treatment. This method provides a significant advance over current invasive methods and has important implications for patient care.
Researchers at Boston Medical Center identified specific virus characteristics that can help predict the efficacy of HIV-1 treatments using antibody-based treatments. These findings will enable physicians to make better-informed decisions on treatment plans for patients with HIV-1, ultimately treating the virus to slow it down earlier.
Antibodies recognize viruses and cancer cells via Fab arms, but now researchers know the Fab portion also directly binds to Fc receptors. This discovery opens up a new strategy for developing therapeutic antibodies with enhanced binding properties.
A novel antibody-enzyme fusion has virtually eliminated Lafora bodies in LD mouse brains, restoring normal brain metabolism. The therapy has potential treatment applications beyond Lafora Disease, including other glycogen storage diseases.
Scientists developed a tumor-activatable antibody nanoparticle to overcome immunological tolerance in tumors. The nanoparticle releases PD-L1, triggering tumor antigen release and CTL infiltration, leading to efficient antitumor immunity and long-term immune memory effects.
Scientists have developed edible antibodies that can survive digestion and reach the gut, offering an alternative to traditional treatments. The technology has potential applications in fighting gut infections, treating inflammatory disorders, and preventing diarrhea in pigs and humans.
Researchers have identified an association between a MUC5B gene variant and systemic vasculitis, a lung disease prevalent in the Japanese population. The study found that patients with antineutrophil cytoplasmic antibody-associated vasculitis are more likely to have ILD if they carry this specific genetic variation.
The company has isolated rare inhibitory MAbs against CB1 using its MPS Antibody Discovery platform, offering a therapeutic solution for NASH. With over 10 million people affected in the US, this development could bring new hope to those suffering from liver disease and metabolic disorders.
Researchers at the University of Turku developed an immunotherapeutic antibody therapy that re-educates tumour-associated macrophages to activate cytotoxic T cells. The therapy showed promising results in a phase I/II clinical trial, inhibiting cancer progression and increasing activation of killer T cells.
Researchers at The Wistar Institute developed novel synthetic DNA-encoded monoclonal antibodies targeting PCSK9, which significantly reduced cholesterol levels in preclinical studies. This approach may provide a less frequent and cost-effective alternative to statins for treating high cholesterol and reducing cardiovascular risk.
Researchers found that a combination of multiple antibodies targeting distinct regions of HIV can suppress the virus and prevent resistance. In a pilot clinical trial, participants who received infusions of broadly neutralizing antibodies maintained viral suppression for over 15 weeks after stopping antiretroviral therapy.
Scientists have discovered a set of powerful broadly neutralizing antibodies in the blood of Ebola survivors, providing substantial protection against disease caused by three Ebola virus species. The researchers hope that these antibodies will serve as promising candidates for further development as therapeutic molecules.
Researchers at the University of Helsinki have identified a monoclonal antibody that inhibits capillary leakage in sepsis. The antibody targets β1-integrin, a key molecule in endothelial cells, and improves junctions between endothelial cells, decreasing vascular leakage and protecting against sepsis-induced heart failure.
A collaborative study led by the University of Miami Miller School of Medicine found that a monoclonal antibody cocktail therapy was effective in clearing the virus from pregnant women's blood but failed to prevent fetal transmission and treat infected fetuses. Researchers are now working on engineering antibodies to target the fetus.
Researchers develop therapeutic antibodies targeting the C-terminus of Sonic hedgehog, a protein involved in tissue homeostasis and repair. These antibodies show promise in inhibiting cancer cell growth and tumor formation in preclinical models.
AbeXXa Biologics has partnered with global pharmaceutical company Boehringer Ingelheim to develop a novel approach to cancer immunotherapy. The partnership aims to create personalized therapies tailored to each patient's tumor using atypical HLAs, which have less variability than classical HLAs.
Researchers from Osaka University have identified an antibody that alleviates symptoms in neuromyelitis optica in rats by suppressing RGMa. The study uses a new localized animal model to investigate the correlation between inflammation and motor function disruption.
Scientists at UTHealth and UT Health San Antonio are developing an innovative antibody-based drug to stem the spread of breast cancer to bone, linked to reduced survival rates. The goal is to create a less toxic treatment and reduce deaths tied to breast cancer's spread.
Researchers have developed a new leukemia therapy that combines inhibitors with immune therapies to eliminate cancer cells, showing promising results in preclinical trials. The combination of treatments worked better than using one active substance alone.
Researchers developed an efficient method to produce antibodies that can bind to two different target molecules simultaneously, enhancing cancer immunotherapy. The new approach uses a modified IgG antibody structure with only four key changes, allowing for more versatile formats and improved stability.
Researchers at The Wistar Institute have developed a gene-based delivery system that instructs the body to generate therapeutic antibodies against cancer cells. This technology has shown promising results in treating prostate cancer by binding to cancer cells and recruiting immune cells, resulting in tumor shrinkage and improved survival.
Researchers found that co-administering an antibody that neutralizes tumor-released soluble MHC I chain-related molecule (sMIC) improves anti-CTLA4 therapy effectiveness and reduces treatment-related colitis. The combination therapy dramatically improves CTLA4 therapy response and avoids colitis, suggesting a new powerful immunotherapy...
Researchers discovered that tumor-associated macrophages steal checkpoint blockade antibodies from T cells, leading to improved responses in mouse models. Blocking FcγR receptors allows checkpoint inhibitors to effectively target cancer cells.
Researchers have explored the potential of this novel therapeutic approach, demonstrating promising pre-clinical data with over 40 scientific papers. Vectored-antibody delivery using rAAV offers advantages in treatment of various chronic and infectious diseases.
Researchers have discovered an antibody that can detect tau in the serum of patients with tauopathies, a neurodegenerative disorder characterized by toxic protein clumps. The antibody, HJ8.5, has shown promise in increasing tau levels in human patients and mouse models, potentially paving the way for new treatments.
Researchers have developed a new method to create antibodies with consistent sugar groups, enhancing their ability to signal the immune system. This breakthrough could lead to more effective therapies for cancer and autoimmune diseases, with the potential for customized antibody production.
A team from the University of Pennsylvania has demonstrated a new method to deliver safer and more cost-effective therapeutic antibodies using messenger RNAs. The technique involves injecting modified mRNAs into cells, which then produce the therapeutic proteins in a controlled manner.
Researchers have identified a specific site on the surface of the human astrovirus that can be targeted for development of a vaccine or antiviral therapy. By binding to this site, neutralizing antibodies can block the virus's ability to infect human cells, providing a potential roadmap for treatment options.